Allergy specialist ALK hits record high after another outlook hike
23/08/2024 08:47
** Shares in ALK-Abello ALKb.CO rise 10% to DKK 177.8, its
highest level ever, as the Danish allergy solutions maker
delivers Q2 revenue beat and yet again raises its FY outlook
** ALK now expects revenue to grow by 14-16% in local
currencies compared to the earlier view of 12-15%, and EBIT
margin to reach 19-21% (prev: 18-20%)
** Q2 sales came in at DKK 1,374 mln for the Danish company,
5% ahead of the company compiled consensus
** ALK attributes the revenue growth to a continued strong
momentum in tablet sales
** Jefferies notes that the tablet sales beat estimates by
7% driven primarily by Europe
** The outlook hike is the third so far this year for the
Danish company
** The stock is the best performer on pan-European
STOXX .STOXX 600 index
(Reporting by Tilla Sjaavaag)
((tilla.sjaavaag@thomsonreuters.com))